Dorian Gray from all over the world, unite: the "young blood" clinic is back.
Ambrosia again sells plasma obtained from young blood (from people aged 16 to 25) for transfusions on healthy subjects who believe they obtain health benefits from this practice.
For a period the company had embraced a different name (Ivy Plasma), but has retraced its steps. Ambrosia project is actually cooler.
“Customers really love the Ambrosia name and brand, so we keep going,” says Jesse Karmazin, founder of Ambrosia and firm supporter of young blood transfusions.
Old name, new business
With the return to the old name, Ambrosia decided to innovate in the business model: previously the clinic carried out transfusions directly in the American cities of San Francisco and Tampa.
Today Ambrosia continues to carry out transfusions only in San Francisco, but sends its plasma directly to the doctors who will then carry out the transfusion, avoiding customers having to fly to California.
“We deliver plasma to doctors within 12 hours, and provide them with instructions on transfusions,” says Karmazin. “In this way the number of treatable patients has increased enormously”.
The return to the origins of Ambrosia is not a purely affective fact, but follows a statement in which the FDA warned that young blood transfusions had no health benefit. In simple terms? For the American authority (and many experts) the practice would be a dangerous scam.
Those who argue otherwise attribute to this expensive treatment (8000 euros per litre) the ability to provide greater youth, greater longevity, the reversal of memory loss and other wonders.
Karmazin himself presented the clinic in a conference two years ago by saying "we are a company interested in making you young again". Here is the video (In English) :
Given the FDA's warning, Karmazin's clinic changed its name to Ivy Plasma, and began selling plasma, offering patients treatments "at their own risk", so as to legally protect themselves from possible lawsuits. Is it selling blood or is it a donation for payment of money? Goat wool issues, such as cost issues, that don't change the substance. Poor Avis.
With the return to the old name Ambrosia does not eliminate the practice but provides more details on the treatment.
“In all tests our treatment showed statistically significant improvements. Specifically, in biomarkers linked to Alzheimer's syndrome, cancer, inflammation and more,” reads on the official website. “Patients have reported benefits in memory, agility, skin quality, sleep and other areas.”
When asked if the FDA rules had become more lenient, Karmazin showed no particular concern about any sanctions for claims made on his website.
"I'm calm, we will continue to offer patients this type of treatment."
